Cost-Effectiveness Analysis of Entecavir versus Lamivudine in the First-Line Treatment of Australian Patients with Chronic Hepatitis B

Author： Arnold Elizabeth

Publisher： Adis International

ISSN： 1175-5652

Source： Applied Health Economics and Health Policy, Vol.6, Iss.4, 2008-01, pp. : 231-246

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Economics of Hepatitis B Virus Vaccination: An Analysis of Cost-Effectiveness Results for Switzerland

By Zurn P.

Disease Management & Health Outcomes, Vol. 7, Iss. 6, 2000-06 ,pp. : 331-347

Adis International

Access to resources Recommend Favorite

Vaccination against hepatitis B virus in Spain: a cost-effectiveness analysis

By Garuz R. Torrea J.L. Arnal J.M. Forcen T. Trinxet C. Anton F. Antonanzas F.

Vaccine, Vol. 15, Iss. 15, 1997-10 ,pp. : 1652-1660

Elsevier

Access to resources Recommend Favorite

Cost-effectiveness of hepatitis B vaccination of prison inmates

By Pisu M. Meltzer M.I. Lyerla R.

Vaccine, Vol. 21, Iss. 3, 2002-12 ,pp. : 312-321

Elsevier

Access to resources Recommend Favorite

Management of Chronic Hepatitis B: Defining the Role of Lamivudine

By Jarvis B. Perry C.M.

Disease Management & Health Outcomes, Vol. 9, Iss. 4, 2001-01 ,pp. : 215-234

Adis International

Access to resources Recommend Favorite

Immunization programme against hepatitis B virus infection in Italy: cost-effectiveness

By Da Villa G. Sepe A.

Vaccine, Vol. 17, Iss. 13, 1999-01 ,pp. : 1734-1738

Elsevier

Access to resources Recommend Favorite